Philipp S. Muether - Concepedia

Author

Philipp S. Muether

Also Known As

Muether, P.S., Muether, Philipp S., P S Muether, P. Muether, P. S. Muether, P.S. Muether, PHILIPP S. MUETHER, Philipp Muether, Philipp S Muether, Philipp S. Muether

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

University of Cologne University Hospital Cologne Helios Dr. Horst Schmidt Kliniken Wiesbaden Radboud University Nijmegen McGill University Health Centre

About

Philipp S. Muether is an author at University of Cologne specializing in medicine, ophthalmology, and age-related diseases.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	996
2	Public Health	2	2	156
3	Engineering	1	1	40
4	Allergy	1	1	54
5	Allergy Medicine	1	1	54

Philipp S. Muether

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Overexpression of HTRA1 Leads to Ultrastructural Changes in the Elastic Layer of Bruch's Membrane via Cleavage of Extracellular Matrix Components Sarah Vierkotten, Philipp S. Muether, Sascha Fauser PLoS ONE Membrane StructureOcular DiseaseGeneticsExtracellular Matrix ComponentsCellular Physiology	2011	149
Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life Katharina M. Droege, Philipp S. Muether, Manuel M. Hermann, Graefe s Archive for Clinical and Experimental Ophthalmology Ocular DiseaseOphthalmologyAge-related DiseasesEye HealthReal Life	2012	114
Cumulative Effect of Risk Alleles in CFH, ARMS2, and VEGFA on the Response to Ranibizumab Treatment in Age-related Macular Degeneration Dženita Smailhodzic, Philipp S. Muether, John Chen, Ophthalmology Ocular DiseaseCumulative EffectOphthalmologyAge-related DiseasesGenetic Epidemiology	2012	110
Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration Philipp S. Muether, Robert Hoerster, Manuel M. Hermann, Graefe s Archive for Clinical and Experimental Ophthalmology Ocular DiseaseLong-term EffectsOphthalmologyAge-related DiseasesEye Health	2012	86
Suppression of Intraocular Vascular Endothelial Growth Factor During Aflibercept Treatment of Age-Related Macular Degeneration Sascha Fauser, Viktoria Schwabecker, Philipp S. Muether American Journal of Ophthalmology Ocular DiseaseOphthalmologyAflibercept TreatmentAge-related DiseasesImmunology	2014	81
Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity Philipp S. Muether, Manuel M. Hermann, Konrad R. Koch, Graefe s Archive for Clinical and Experimental Ophthalmology Anti-vegf TreatmentDiabetic RetinopathyOcular DiseaseOphthalmologyAge-related Diseases	2010	78
Vascular Endothelial Growth Factor in Patients with Exudative Age-related Macular Degeneration Treated with Ranibizumab Philipp S. Muether, Manuel M. Hermann, Ulrike Viebahn, Ophthalmology Ocular DiseaseOphthalmologyAge-related DiseasesPathologyVascular Biology	2012	74
Immunohistochemical localization of complement regulatory proteins in the human retina. Anna L Fett, Manuel M. Hermann, Philipp S. Muether, PubMed	2012	67
Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times Sascha Fauser, Philipp S. Muether British Journal of Ophthalmology	2016	62
Macular morphology in former preterm and full-term infants aged 4 to 10 years Achim Fieß, Johannes Janz, Alexander K. Schuster, Graefe s Archive for Clinical and Experimental Ophthalmology Ocular DiseaseOphthalmologyPediatricsMacular MorphologyPediatric Ophthalmology	2017	60

Page 1